A Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of K0706 in Plasma and Cerebrospinal Fluid in Healthy Volunteers
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Oct 2019
Price : $35 *
At a glance
- Drugs SUN K706 (Primary)
- Indications Chronic myeloid leukaemia; Lewy body disease; Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Sun Pharma Advanced Research Company
- 15 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 22 Jul 2019 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
- 22 Jul 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Dec 2019.